Optimization of topical formulations for the treatment of basal cell carcinoma using the Feldan Shuttle technology

使用 Feldan Shuttle 技术优化治疗基底细胞癌的局部制剂

• 批准号: 549971-2020
• 负责人: Fortier, IsabelleI
• 金额: $ 9.11万
• 依托单位: Cégep de Lévis
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 3
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=765527
• 关键词: Optimization; topical; formulations; treatment; basal

This ARD proposal aims at validating the efficiency of new proprietary drug formulations for the treatment of skin cancers. In this research project, a preclinical model will be used and validated to demonstrate the efficacy of the formulation as well as its superiority compared to non-formulated treatment. This project will strongly support the supporting partner by addressing technical questions in the context of skin-applied treatments that will enhance significantly their portfolio to support their economic growth and target markets. Moreover, these formulations may provide significant improvement for patients having basal cell carcinoma or the genetic syndrome termed Gorlin Syndrome where recurrent tumoral lesions are occurring leading to problematic need for serial surgery or systemic treatment with adverse effects.

该ARD提案旨在验证用于治疗皮肤癌的新专利药物制剂的有效性。在本研究项目中，将使用临床前模型并进行验证，以证明该制剂的疗效及其与非制剂治疗相比的优效性。该项目将通过解决皮肤应用治疗方面的技术问题来大力支持支持合作伙伴，这将大大增强其产品组合，以支持其经济增长和目标市场。此外，这些制剂可以为患有基底细胞癌或称为Gorlin综合征的遗传综合征的患者提供显著的改善，其中发生复发性肿瘤病变，导致对具有副作用的连续手术或全身治疗的有问题的需要。